Issue 7/2025
Valeva, E., Vassileva, S., Tamnev, S., Drenovska, K.
Department of Dermatology and Venereology, Medical University – Sofia
Autoimmune bullous dermatoses (AIBDs) represent a heterogeneous group of rare disorders characterized by a chronic and progressive course, for which long-term therapeutic management remains a considerable challenge in dermatological practice. The Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling pathway plays a pivotal role in the pathogenesis of numerous inflammatory and autoimmune conditions. Recently, a variety of pharmacological agents known as JAK-inhibitors have been developed with the aim of selective targeting and inhibiting this signaling cascade which was found applicable in various fields of dermatology and especially in the treatment of psoriasis, atopic dermatitis, alopecia, vitiligo, etc. Increasing attention has been directed also towards their potential use in the treatment of various forms of AIBDs. The aim of the present review is to summarize the available data on the efficacy and safety of this new class of medications in the therapy of AIBDs.
Key words: autoimmune bullous dermatoses, JAK-inhibitors
Address for correspondence:
Dr. Elia Valeva
Department of Dermatology and Venereology,
Medical University – Sofia, UMHAT “Alexandrovska”
1, “St. Georgi Sofiyski”, Str.
1431, Sofia
email: valeva.elia@gmail.com